Core Viewpoint - Centene experienced a significant drop in stock price, closing down over 40% on July 2, resulting in a loss of over $11 billion in market capitalization, with competitors also facing declines [1][2][5] Group 1: Financial Impact - The drop in Centene's shares was primarily due to the withdrawal of its 2025 full-year guidance, indicating a more challenging financial outlook [2][4] - The company received data indicating lower growth in the ACA exchange market and higher morbidity among enrollees, leading to fewer and sicker patients [3][4] - The expected impact on Centene's 2025 diluted earnings per share (EPS) is a reduction of $2.75, which is 38% of the previously expected EPS of greater than $7.25 [4][5] Group 2: Market Valuation - Despite the significant stock sell-off, Wall Street analysts see a more attractive valuation for Centene, with a 12-month price target of $68.87, implying a potential upside of 108.31% from the current price [5][6] - The average price target post-guidance withdrawal is $51, suggesting a 53% upside, which is higher than the 32% average upside prior to the drop [6][7] Group 3: Regulatory Environment - The recent legislation signed into law includes $1 trillion in cuts to Medicaid, which accounted for approximately 46% of Centene's revenue last quarter, potentially leading to 10.3 million to 11.8 million fewer Medicaid recipients over the next decade [8][9] - The reduction in expected Medicaid users could have a more significant and lasting impact on Centene compared to the ACA exchange enrollment issues, which only made up 20% of the firm's total revenue last quarter [9]

Core Viewpoint - Centene Corporation is under investigation for potential violations of federal securities laws due to allegations of providing misleading business information, which has led to significant stock price decline following the withdrawal of its earnings guidance [1][4]. Company Overview - Centene is a managed healthcare company that specializes in government-sponsored programs such as Medicaid and Medicare, as well as health insurance plans on individual exchanges and commercial marketplaces [3]. Alleged Wrongdoing - On July 1, 2025, Centene announced its decision to withdraw its 2025 earnings guidance, citing declining market growth in 22 out of the 29 states it operates in. The company indicated that health risks in these states were much higher than previously anticipated in its risk adjustment calculations [4]. - Following this announcement, Centene's stock price dropped by $22.87 per share, representing a 40.37% decline, closing at $33.78 per share on July 2, 2025 [4].

Core Viewpoint - Centene Corporation is facing potential legal claims regarding violations of federal securities laws and unlawful business practices following a significant drop in stock price after withdrawing its 2025 earnings guidance [1][2]. Group 1: Company Performance - On July 2, 2025, Centene's stock price fell over 39.5% during intraday trading after the company announced the withdrawal of its 2025 earnings guidance due to higher-than-expected costs related to Medicaid enrollees and underperformance in its Affordable Care Act plans [2]. - The company indicated that its Medicaid business has seen an increase in medical cost trends in areas such as behavioral health, home health, and high-cost drugs [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Centene on behalf of its stockholders, focusing on whether the company has violated federal securities laws [1]. - The law firm is reaching out to long-term stockholders who may have suffered losses or have information regarding these claims [3].

Group 1 - Centene Corporation is under investigation for potential securities fraud and unlawful business practices involving its officers and directors [1] - On July 1, 2025, Centene withdrew its 2025 GAAP and adjusted diluted earnings per share guidance due to underperformance in market growth across 22 out of 29 states and higher-than-expected health risks affecting revenue calculations [2] - Following the announcement, Centene's stock price dropped by $22.87, or 40.37%, closing at $33.78 per share on July 2, 2025 [3] Group 2 - Pomerantz LLP is a prominent law firm specializing in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Centene Corp. experienced a significant share price drop of 40% after withdrawing its revenue guidance due to unexpected data from an independent actuary, raising concerns about potential violations of securities laws [1][2][5]. Company Overview - Centene Corp. positions itself as a leading healthcare enterprise, focusing on providing integrated services to government-sponsored and commercial healthcare programs, particularly for under-insured and uninsured individuals [3]. - The company offers products to individuals, including Medicare and Medicaid members, as well as those insured by the Health Insurance Marketplace [3]. Financial Guidance and Adjustments - On April 25, 2025, Centene raised its 2025 revenue guidance by $6 billion and reaffirmed its GAAP diluted EPS guidance floor of greater than $6.19 and adjusted diluted EPS guidance floor of greater than $7.25 [4]. - On July 1, 2025, Centene withdrew its previous guidance, citing new information regarding Health Insurance Marketplace data [5]. Market Data and Implications - The company analyzed initial 2025 industry Marketplace data from Wakely, covering 22 states, which represented approximately 72% of its Marketplace membership [6]. - The analysis revealed that market growth in these states was lower than expected, with significantly higher implied market morbidity than previously assumed, affecting risk adjustment revenue transfer [7]. - Centene estimated a reduction in its full-year net risk adjustment revenue transfer expectation by approximately $1.8 billion, impacting adjusted diluted EPS by about $2.75 [8]. Investor Reaction - Following the announcement of the guidance withdrawal and the negative market data, Centene's share price fell by 40%, equating to a loss of $22.87 per share in a single day [9].

Core Viewpoint - Centene Corporation is facing an investigation regarding potential securities fraud and unlawful business practices following its withdrawal of earnings guidance due to disappointing market growth and higher-than-expected health risks [1][3]. Group 1: Company Performance - On July 1, 2025, Centene announced the withdrawal of its 2025 GAAP and adjusted diluted earnings per share (EPS) guidance, citing that market growth in 22 out of 29 states was not meeting expectations [3]. - The company indicated that the overall health risks in these states were significantly higher than anticipated, impacting its risk adjustment revenue calculations [3]. Group 2: Market Reaction - Following the announcement, Centene's stock price experienced a significant decline, falling by $22.87 per share, or 40.37%, closing at $33.78 per share on July 2, 2025 [4]. Group 3: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Centene investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Insights - Centene Corporation experienced a significant stock decline of nearly 40% on July 2 after withdrawing its full-year guidance, attributing the drop to challenges in its Medicaid and Affordable Care Act (ACA) businesses [1][8] - The company's stock closed at $33.31, marking a 38% decrease over the past week [1] Group 1: Stock Performance and Legislative Context - Four U.S. House members sold Centene shares between May 12 and May 30, prior to the company's warning and the passage of the One Big Beautiful Bill Act (OBBBA), which cuts Medicaid funding by $1 trillion over the next decade [3][4] - The OBBBA, passed on July 3, imposes stricter Medicaid work requirements and eligibility checks, potentially removing 10 to 12 million Americans from coverage by 2034 [8] - The timing of congressional stock trades has raised concerns about potential insider trading, given the direct impact of legislation on Centene [9] Group 2: Financial Impact and Market Conditions - Centene disclosed that enrollment and cost trends would reduce earnings by $2.75 per share [8] - The company is facing challenges as healthier enrollees are dropping coverage following the rollback of pandemic-era benefits, resulting in fewer, higher-cost members and squeezing earnings [9] - Critics of the OBBBA warn that it could severely impact low-income families and rural healthcare providers, while supporters argue it will help reduce fraud and abuse [8]

Core Viewpoint - Centene Corp. experienced a significant 40% drop in share price after withdrawing its revenue guidance due to unexpected data from an independent actuary, raising concerns about potential violations of securities laws [1][5][9]. Company Overview - Centene Corp. positions itself as a leading healthcare enterprise, focusing on providing integrated services to government-sponsored and commercial healthcare programs, particularly for under-insured and uninsured individuals [3]. Financial Guidance and Adjustments - On April 25, 2025, Centene had increased its 2025 revenue guidance by $6 billion and reaffirmed its GAAP diluted EPS guidance floor of over $6.19 and adjusted diluted EPS guidance floor of over $7.25 [4]. - On July 1, 2025, Centene withdrew its previous guidance, citing new information regarding Health Insurance Marketplace data [5]. Market Data Analysis - The company analyzed initial 2025 industry Marketplace data from Wakely, covering 22 states, which represented approximately 72% of its Marketplace membership [6]. - The analysis revealed lower-than-expected overall market growth and higher-than-anticipated market morbidity, leading to a reduction in the expected net risk adjustment revenue transfer by approximately $1.8 billion, impacting adjusted diluted EPS by about $2.75 [7][8]. Investor Reaction - Following the announcement of the guidance withdrawal and the negative data, Centene's share price fell by 40%, equating to a loss of $22.87 per share in a single day [9].

Live from Washington, D. C. This is balance of power with Jo Matthew and Kaylee Lyons.Republicans still do not have the votes to pass the president's big, beautiful bill once and for all. Welcome to the Wednesday edition. As the House grinds through a series of procedural votes that should set up a final decision at some point, we just don't know when I'm show matthew alongside Kailey Leinz in washington.We thank you for joining us here. A number of issues, kelly, could potentially slow this process, not th ...

Global Market Overview - The Hang Seng Index closed at 24,221, down 0.26% for the day but up 42.08% year-to-date [1] - The S&P 500 in the US closed at 6,227, up 0.88% for the day and 30.56% year-to-date [1] - The DAX in Germany closed at 23,790, down 1.01% for the day but up 42.02% year-to-date [1] Sector Performance - In the Hong Kong market, the Hang Seng Financial Index rose 0.06% for the day and is up 48.18% year-to-date, while the Hang Seng Real Estate Index increased by 1.22% but is down 2.68% year-to-date [2] - The Chinese stock market saw gains in energy, real estate, and materials, while information technology, healthcare, and telecommunications lagged [3] Investment Opportunities - Geely Automobile (175 HK) is rated as a "Buy" with a target price of 24.00, representing a potential upside of 47% from its current price of 16.32 [4] - Xpeng Motors (XPEV US) is also rated as a "Buy" with a target price of 28.00, indicating a 52% upside from its current price of 18.37 [4] - Tencent (700 HK) has a target price of 660.00, suggesting a 32% upside from its current price of 501.50 [4] Economic Indicators - The US ADP employment data unexpectedly declined, raising expectations for interest rate cuts, while the two-year Treasury yield fell [3] - The market is closely watching the upcoming non-farm payroll data, which may reflect a dual impact from economic slowdown and reduced labor supply due to immigration policies [3]